GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

CanaQuest Medical CANQF · USD

N/A · US listing · 🇺🇸 United States

Compare

0.00

—

Close of 30 Oct 2026, in USD

At a glance

Figures in CAD, from our data supplier.

FY2024

Revenue

C$45,945

FY2015FY2024

Net income

−C$1.9m

FY2015FY2024

Free cash flow

−C$370,778

FY2015FY2024

Shareholders' equity

−C$1.5m

FY2015FY2024

Income statement

Fiscal years

FY2024FY2023FY2022FY2020FY2019FY2018FY2017FY2016FY2015
RevenueC$45,945——C$29,242—————
Research and developmentC$56,503C$42,063C$22,909C$81,491C$301,917C$262,007C$7,629C$3,184C$71,373
Operating income−C$1.9m−C$1.2m−C$770,337−C$1.3m−C$962,640−C$1.3m−C$1.8m−C$1.8m−C$1.1m
Net income−C$1.9m−C$1.1m−C$746,106−C$1.3m−C$1.1m−C$1.1m−C$2.6m−C$1.9m−C$1.1m
Diluted earnings per share-0.09-0.05-0.04-0.06-0.06-0.05-0.19-0.18-0.12

Balance sheet

At each fiscal year end

FY2024FY2023FY2022FY2020FY2019FY2018FY2017FY2016FY2015
Total assetsC$291,613C$190,724C$87,221C$67,550C$74,922C$110,319C$92,756C$109,243C$142,086
Cash and short-term investmentsC$106C$5,541C$20,688C$596C$4,158C$8C$87C$173C$3,084
Total liabilitiesC$1.8mC$1.6mC$945,285C$780,003C$810,083C$948,251C$897,442C$809,347C$894,022
DebtC$509,976C$859,324C$432,121C$150,955C$152,284C$153,579C$91,426C$386,564—
Shareholders' equity−C$1.5m−C$1.4m−C$858,063−C$712,453−C$735,160−C$837,932−C$804,686−C$700,104−C$751,936
Shares outstanding21m21m21m20m20m20m13m11m9m

Cash flow

Fiscal years

FY2024FY2023FY2022FY2020FY2019FY2018FY2017FY2016FY2015
Cash from operations−C$370,777−C$660,040−C$238,466−C$48,570−C$1.1mC$27,539−C$341,945−C$209,919−C$252,077
Capital spending−C$1−C$4,056−C$16,105—−C$5———−C$64,699
Free cash flow−C$370,778−C$664,096−C$254,571−C$48,570−C$1.1mC$27,539−C$341,945−C$209,919−C$316,776

Latest quarters

By quarter end

Dec 2024Sept 2024Jun 2024Mar 2024Dec 2023Sept 2023Jun 2023Mar 2023
RevenueC$13,585C$12,871C$13,204C$17,928C$16,420C$11,183——
Operating income−C$205,272−C$295,432−C$282,685−C$952,118−C$664,933−C$122,043−C$92,865−C$157,799
Net income−C$205,842−C$406,332−C$462,431−C$950,795−C$659,200−C$107,301−C$143,889−C$163,963
Diluted earnings per share-0.01-0.02-0.02-0.04-0.03-0.01-0.01-0.01
Total assetsC$201,160C$301,651C$169,642C$291,613C$436,894C$512,638C$226,496C$190,724
Cash and short-term investmentsC$4,818C$66C$82C$106C$1,857C$20,345—C$5,542
DebtC$153,000C$243,589C$443,802C$509,976C$598,611C$611,589C$742,199C$859,324
Shareholders' equity−C$1.2m−C$1.6m−C$1.6m−C$1.5m−C$1.1m−C$1.3m−C$1.3m−C$1.4m

Growth per year

Compound annual rate

3 years5 years10 years
Revenue234.5%——
Operating income91.2%14.0%19.3%
Net income94.9%11.1%19.2%

Valuation history

At each fiscal year end

FY2024
Price to earnings-0.1
Price to sales2.3

Share price return

Finished calendar years

20252024
Return-95%-0%

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.